ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Arthritis

Arthritis

A new study reveals two possible biomarkers for methotrexate resistance, and also reveals more about how methotrexate works.

There's good reason why it's difficult to "catch" rheumatoid arthritis early enough to assure remission. Patients with early symptoms seek care only when they sense a threat. (Can this be solved?)

psoriatic arthritis

Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.

The JAK1 and JAK2 inhibitor baricitinib has shown significant results in a second Phase 3 trial for rheumatoid arthritis.

The first study to ask about variance between physicians and patients in judging the severity of psoriatic arthritis shows that, as with rheumatoid arthritis, they don't reach similar conclusions.

Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.

juvenile arthritis

The TNF-α blocker improved growth rates for many preadolescent girls with juvenile arthritis, especially those who hadn't been taking steroids.

Pages

Subscribe to Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.